Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer-Reference-Cited by-同舟云学术

Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer

Published:2023-02 Issue:2 Volume:4 Page:100937
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Dhital Brittiny,Santasusagna Sandra,Kirthika Perumalraja,Xu Michael,Li Peiyao,Carceles-Cordon Marc,Soni Rajesh K.,Li Zhuoning,Hendrickson Ronald C.,Schiewer Matthew J.,Kelly William K.,Sternberg Cora N.,Luo Jun,Lujambio Amaia,Cordon-Cardo Carlos,Alvarez-Fernandez Monica,Malumbres Marcos,Huang Haojie,Ertel Adam,Domingo-Domenech Josep,Rodriguez-Bravo Veronica^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference121 articles.

1. The mutational landscape of lethal castration-resistant prostate cancer;Grasso;Nature,2012

2. Integrative genomic profiling of human prostate cancer;Taylor;Cancer Cell,2010

3. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis;Lapointe;Cancer Res.,2007

4. Paradoxical relationship between chromosomal instability and survival outcome in cancer;Birkbak;Cancer Res.,2011

5. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers;Carter;Nat. Genet.,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerin mislocalization during chromatin bridge resolution can drive prostate cancer cell invasiveness in a collagen-rich microenvironment;Experimental & Molecular Medicine;2024-09-02

2. Pauperization of Emerin from nuclear envelope during chromatin bridge resolution drives prostate cancer cell migration and invasiveness;2024-04-12

3. The two sides of chromosomal instability: drivers and brakes in cancer;Signal Transduction and Targeted Therapy;2024-03-29

4. Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies;Scientific Reports;2024-02-23

5. TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling;Molecular Oncology;2024-02-15